- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
September 5, 2024Roman Silberfeld Named Among Daily Journal’s Top 100 Lawyers
-
September 3, 2024B. Todd Jones Returns to Robins Kaplan LLP as Partner
-
August 19, 2024Four Partners Named to IAM Strategy 300 List of Leading IP Strategists
-
September 13, 2024LGBTQ Legal Services: Transgender Name Change Clinic
-
September 16, 2024Understanding Trusts Seminar
-
September 17, 2024Hot Torts:
-
August 2024Recruiting & Retaining Diverse Attorneys: Building an Inclusive Legal Profession
-
August 22, 2024Prior Art Takeaways From Fed. Circ. Public Disclosure Ruling
-
August 13, 2024Playing Dungeons & Dragons Makes Me A Better Lawyer
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Generic Launches Q3 2012
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
November 11, 2012
Reference Listed Drug |
NDA Holder |
Generic Drug Name |
ANDA Applicant(s) |
Indication |
Launch Date |
Boniva |
GlaxoSmithKline/Roche |
ibandronate sodium tablets |
Dr. Reddy's Labs |
Osteoporosis |
July 2, 2012 |
Lescol |
Novartis |
fluvastatin capsules, USP |
Teva |
Antilipemic/statins |
Jul. 2, 2012 |
Clarinex |
Schering-Plough |
desloratadine tablets |
Mylan |
Allergy medication |
July 3, 2012 |
Lithobid Tablets |
Noven Therapeutic |
lithobid carbonate extended release tablets USP |
Mylan |
Bipolar disorder |
Jul. 3, 2012 |
Plan B One-Step |
Teva |
levonorgestrel tablets |
Watson Labs |
Prevention of pregnancy |
Jul. 13, 2012 |
Ritalin LA Extended Release Capsules |
Novartis |
methylphenidate hydrochloride extended release capsules |
Teva |
ADHD |
July 16, 2012 |
Lipitor |
Pfizer |
atorvastatin calcium tabs |
Dr. Reddy's Labs |
High cholesterol |
Jul. 18, 2012 |
Oxacillin Sodium ADD-Vantage |
Sandoz |
oxacillin for injection |
Sagent Pharm |
Antibiotic |
Jul. 24, 2012 |
Sporanox |
Janssen Pharmaceutical |
itraconazole capsules |
Mylan |
Fungal infections in the lungs, blastomycosis, histoplasmosis and aspergillosis |
Jul. 27, 2012 |
Oxycodone |
Lehigh Valley |
oxycodone hydrochloride |
Coastal Pharmaceuticals |
Pain management |
Jul. 30, 2012 |
Methotrexate sodium |
Quad Pharms |
methotrexate injection |
Teva |
Antineoplastics |
Jul. 31, 2012 |
Dovonex |
LEO Pharma |
calcipotriene cream |
Sandoz |
Plaque psoriasis |
Aug. 3, 2012 |
Singulair Tablets and Singulair Chewable Tablets |
Merck |
montelukast sodium tablets and montelukast sodium chewable tablets |
Roxane |
Asthma and allergies |
Aug. 3, 2012 |
Singulair Tablets and Singulair Chewable Tablets |
Merck |
montelukast sodium tablets and montelukast sodium chewable tablets |
Teva |
Asthma and allergies |
Aug. 3, 2012 |
Amidate Injection |
Hospira |
etomidate injection USP |
Mylan |
Induction of general anesthesia |
Aug. 6, 2012 |
Singulair Tablets and Singulair Chewable Tablets |
Merck |
montelukast sodium tablets and montelukast sodium chewable tablets |
Sandoz |
Asthma and allergies |
Aug. 6, 2012 |
Singulair Tablets and Singulair Chewable Tablets |
Merck |
montelukast sodium tablets and montelukast sodium chewable tablets |
Endo Pharmaceuticals |
Asthma and allergies |
Aug. 6, 2012 |
Singulair Tablets and Singulair Chewable Tablets |
Merck |
montelukast sodium tablets and montelukast sodium chewable tablets |
Glenmark Generics |
Asthma and allergies |
Aug. 6, 2012 |
Singulair Tablets and Singulair Chewable Tablets |
Merck |
montelukast sodium tablets and montelukast sodium chewable tablets |
Mylan |
Asthma and allergies |
Aug. 7, 2012 |
Singulair Tablets and Singulair Chewable Tablets |
Merck |
montelukast sodium tablets and montelukast sodium chewable tablets |
Dr. Reddy's Labs |
Asthma and allergies |
Aug. 7, 2012 |
Morphine Sulfate |
Roxane |
morphine sulfate |
Perrigo |
Opioid analgesic for pain management |
Aug. 8, 2012 |
Clobex Shampoo |
Galderma Labs |
clobetasol propionate shampoo |
Perrigo |
Scalp psoriasis |
Aug, 9, 2012 |
Elaxotin |
Sanofi Aventis |
oxaliplatin for injection |
Hospira |
Chemotherapy |
Aug. 9, 2012 |
Eloxatin |
Sanofi Aventis |
oxaliplatin for injection |
Sagent Pharm |
Stage II colon cancer |
Aug. 9, 2012 |
Lithium Carbonate |
Roxane |
lithium carbonate extended release tablets USP |
Mylan |
Manic episodes of manic depressive illness |
Aug. 10, 2012 |
Provigil Tablets |
Cephalon |
modafinil tablets USP |
Mylan |
Improve wakefulness |
Aug. 10, 2012 |
Eloxatin |
Sanofi Aventis |
oxaliplatin injection |
Teva |
Antineoplastics |
Aug. 13, 2012 |
Uroxatral |
Sanofi Aventis |
alfuzosin hydrochloride |
Wockhardt |
Benign prostatic hyperplasia and enlarged prostate |
Aug. 14, 2012 |
Plavix |
Bristol-Myers Squibb |
clopidogrel bisulfate |
Wockhardt |
Clot-buster |
Aug. 16, 2012 |
Actoplus Met Tablets |
Takeda Pharmaceutical Company |
pioglitazone hydrochloride and metformin hydrochloride |
Mylan |
Anti-diabetic |
Aug. 17, 2012 |
Actos |
Takeda Pharmaceutical Company |
pioglitazone hydrochloride tablet |
Teva |
Anti-diabetic |
Aug. 17, 2012 |
Actos |
Takeda Pharmaceutical Company |
pioglitazone hydrochloride tablet |
Ranbaxy |
Anti-diabetic |
Aug. 17, 2012 |
Actos Tablets |
Takeda Pharmaceutical Company |
pioglitazone hydrochloride tablet |
Mylan |
Anti-diabetic |
Aug. 17, 2012 |
Actosplus Met |
Takeda Pharmaceutical Company |
pioglitazone hydrochloride and metformin hydrochloride |
Teva |
Anti-diabetic |
Aug. 17, 2012 |
Xopenex |
Sunovion Pharmaceuticals |
levalbuterol hydrochloride inhalation solution |
Watson Labs |
Bronchospasm |
Aug. 20, 2012 |
Xopenex |
Sunovion Pharmaceuticals |
levalbuterol hydrochloride inhalation solution |
Prasco |
Bronchospasm |
Aug. 20, 2012 |
Plendil |
AstraZeneca |
felodipine |
Wockhardt |
Anti-hypertension |
Aug. 21, 2012 |
FazaClo |
Jazz Pharmaceuticals |
clozapine tablets |
Teva |
Anti-psychotic |
Aug. 29, 2012 |
Wellbutrin |
GlaxoSmithKline |
bupropion hydrochloride |
Wockhardt |
Anti-depressant |
Sept. 3, 2012 |
Zofran |
Glaxo Group Limited Corporation |
ondansetron for injection |
Sagent Pharm |
Antiemetic for emetogenic cancer chemotherapy |
Sept. 10, 2012 |
Toprol-XL |
AstraZeneca |
metoprolol succinate |
Dr. Reddy's Labs |
Angina and hypertension |
Sept. 11, 2012 |
Prevacid |
Takeda |
lansoprazole |
Wockhardt |
anti-ulcer |
Sept. 17, 2012 |
Amoxil |
GlaxoSmithKline |
amoxicillin tablets |
Dr. Reddy's Labs |
Antibiotic |
Sept. 20, 2012 |
Antivert Tablets |
Pfizer |
meclizine hydrochloride tablets USP |
Mylan |
Nausea and vomiting, and dizziness associated with motion sickness |
Sept. 21, 2012 |
Diovan and Diovan HCT |
Novartis |
valsartan and hydrochlorothiazide tablets |
Sandoz |
High blood pressure |
Sept. 21, 2012 |
Coumadin |
Bristol-Myers Squibb |
warfarin sodium tablets |
InvaGen |
Venous thrombosis |
Sept. 26, 2011 |
Metedete CD/Ritalin LA |
UCB/Novartis |
methylphenidate hydrochloride extended release capsules |
Teva |
ADHD |
Sept. 27, 2012 |
Avapro and Avalide |
Sanofi Aventis |
irbesartan tablets USP and hydrochlorothiazide tablets USP |
Mylan |
Hypertension |
Sept. 28, 2012 |
Vancocin |
Quad Pharms |
vancomycin hydrochloride for injection |
Sagent Pharm |
Antibiotic |
Sept. 28, 2012 |
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.